ARTICLE | Clinical News
AGIX-4207: Began Phase I testing
April 2, 2001 7:00 AM UTC
AtheroGenics Inc. (AGIX), Atlanta, Ga. Product: AGIX-4207 Business: Autoimmune/Inflammation Therapeutic category: Immune modulation Target: TNF-alpha Description: Oral modulator of TNF-alpha Indicatio...